drugset / Trial / NCT06031233
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2028-07
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
Indications
No indication recorded.